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Abstract
Background: Placental malaria (PM) is a leading cause of maternal and infant mortality. Although the accumulation of
parasitized erythrocytes (PEs) and monocytes within the placenta is thought to contribute to the pathophysiology of PM,
the molecular mechanisms underlying PM remain unclear. Based on the hypothesis that excessive complement activation
may contribute to PM, in particular generation of the potent inflammatory peptide C5a, we investigated the role of C5a in
the pathogenesis of PM in vitro and in vivo.
Methodology and Principal Findings: Using primary human monocytes, the interaction between C5a and malaria in vitro was
assessed. CSA- and CD36-binding PEs induced activation of C5 in the presence of human serum. Plasmodium falciparum GPI
(pfGPI) enhanced C5a receptor expression (CD88) on monocytes, and the co-incubation of monocytes with C5a and pfGPI
resulted in the synergistic induction of cytokines (IL-6, TNF, IL-1b,andIL-10),chemokines(IL-8,MCP-1,MIP1a,MI P1 b)a n dt h ea n t i -
angiogenic factor sFlt-1 in a time and dose-dependent manner. This dysregulated response was abrogated by C5a receptor
blockade. To assess the potential role of C5a in PM, C5a plasma levels were measured in malaria-exposed primigravid women in
western Kenya. Compared to pregnant women without malaria, C5a levels were significantly elevated in women with PM.
Conclusions and Significance: These results suggest that C5a may contribute to the pathogenesis of PM by inducing
dysregulated inflammatory and angiogenic responses that impair placental function.
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Introduction
Placental malaria (PM) is a major determinant of maternal and
infant health in the developing world. PM, especially in
primigravidae, can have profound maternal and fetal health
consequences, including anemia, stillbirth, premature delivery,
intrauterine growth restriction (IUGR) and delivery of low birth
weight (LBW) infants [1,2]. The accumulation of Plasmodium
falciparum parasitized erythrocytes (PEs) within the placenta is
believed to be an essential step in the pathogenesis of PM [3]. A
subpopulation of PEs that express novel variant surface antigens
(VSA-PM), specifically adhere to glycosaminoglycan chondroitin
sulfate A (CSA) in the placental intervillous space [3–5].
PM is also characterized by the infiltration of the placenta with
maternal mononuclear cells (mw). The sequestered PEs release
bioactive molecules including those with associated glycosylpho-
sphatidylinositol anchor molecules (pfGPI) that can stimulate
maternal mw [6–10] and fetal syncytiotrophoblast [6,11,12] to
produce inflammatory cytokines, such as TNF and IFN-c, and b-
chemokines including macrophage-inflammatory protein (MIP)-
1a, MIP-1b, monocyte chemoattractant protein-1 (MCP-1), and
macrophage migration inhibitory factor (MIF). These cytokines
and chemokines further recruit, retain, and activate mw in the
placenta [6–8,12,13]. The resultant accumulation of activated mw
is believed to contribute to adverse birth outcomes [14–16].
Although PEs and mw collect in the placenta, how they may
contribute to fetal and placental injury is unknown.
The maintenance of regulated cytokine responses in the
placenta is essential in order to prevent rejection of the
semiallogenic fetoplacental unit and ensure appropriate immuno-
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physiological adaptation that results in a bias towards cytokines
promoting humoral immunity at the expense of cell-mediated
immunity [18]. PM is associated with heightened TH
1-type
responses that disrupt the balance of cytokines at the maternal-
fetal interface [14,16,19,20]. However, the molecular basis
underlying PM-associated cytokine dysregulation, placental im-
munopathology, and adverse birth outcomes is incompletely
understood.
The complement system is an essential component of the innate
immune response to a number of infectious agents. The
complement cascade can be activated by four distinct pathways,
three of which converge at the level of the C3 component, leading
to the cleavage of C3 and C5 to their activated forms, C3a and
C5a, as well as the formation of the terminal membrane attack
complex [21,22]. Recently, a pathway of C5a generation
occurring independently of C3 was described [21,23]. Several
lines of evidence have implicated excessive activation of the
complement system, notably generation of the potent pro-
inflammatory peptide C5a, in mediating deleterious innate host
responses to bacterial and fungal infections and contributing to the
development of sepsis (reviewed in [22]) [21–26]. Sepsis, similar to
severe malaria, is a clinical syndrome characterized by systemic
inflammation and endothelial activation in response to infection
[27,28]. Elevated C5a levels in sepsis have been implicated in
adverse clinical outcomes and death. Blockade of C5a-C5aR
activity in animal models of sepsis prevents end-organ injury and
improves survival [29–31].
Excessive C5a generation has also recently been identified as a
critical mediator of placental and fetal injury in a non-infectious
mouse model of spontaneous miscarriage and IUGR, via
dysregulation of angiogenic factors required for normal placental
development [32]. Activated complement components were
shown to directly induce the release of soluble fms-like tyrosine
kinase-1 (sFlt-1, sVEGFR-1), a potent anti-angiogenic factor that
prevents signaling of vascular endothelial growth factor and
placental growth factor [33]. Excessive levels of sFlt-1 inhibit
placental differentiation and are thought to play a direct role in
pre-eclampsia [34–36] and C5a-associated IUGR and pregnancy
loss [32]. Of note, Muehlenbachs et al. have reported elevated
plasma levels of sFlt-1 in primigravid women with PM [37].
Based on the hypothesis that C5a may play a role in PM by
generating angiogenic factors that mediate IUGR and fetal loss,
we determined whether malaria parasites can activate C5 and if
C5a potentiates the induction of sFlt-1, inflammatory cytokines
and chemokines associated with adverse pregnancy outcomes.
Here we show that CSA- and CD36-binding PEs activate C5, that
C5a and pfGPI cooperate to induce an amplified inflammatory
and anti-angiogenic response to P. falciparum malaria in vitro, and




The laboratory isolates CS2 (CSA-binding) and E8B (ICAM-1
and CD36 binding) were cultured in vitro as described [38,39].
Cultures were routinely treated with mycoplasma removal agent
(ICN),andweretestedand foundnegativeformycoplasmabyPCR.
Mononuclear cell isolation
PBMCs were isolated from healthy volunteers using a Ficoll
gradient as previously described [40]. PBMCs were counted using
a haemocytometer and cell viability was determined by Trypan
blue exclusion test. Cells were plated at a concentration of 2.0610
6
cells/mL (48 well plate) in RPMI 1640 medium supplemented
with 10% heat inactivated FBS and gentamycin (R10G). Cells
were cultured at 37uCi n5 %C O 2 for the time indicated.
Isolation and purification of GPIs from P. falciparum
HPLC-purified P. falciparum GPI (pfGPI) was isolated [41],
conjugated to gold beads and used at a concentration of 300 ng/
ml as previously described [10]. Unconjugated gold beads alone
were added as controls to wells containing media, or C5a
(endotoxin-free; Biovision, USA). All preparations of purified
pfGPIs were tested for endotoxin by Limulus amebocyte lysate
assay prior to use.
Complement assays
PEs, uninfected red blood cells (uRBCs), or media control were
incubated in the presence of 30% serum from malaria naı ¨ve
donors. After 30 min, supernatants were collected and analyzed
for C5 activation. C5a levels in culture supernatants and human
plasma were measured by ELISA (R&D Systems).
Cytokine and chemokine assays
PBMCs were cultured with or without recombinant human C5a
in addition to P. falciparum culture supernatants (1:10 dilution) and
R10G alone as media control, or HPLC-purified GPI (300 ng/
mL) and unconjugated gold beads as a control. C5a concentra-
tions ranging from 1 nM to 100 nM were selected representing a
spectrum of C5a levels ranging from physiologically normal levels
(,10 nM) to those associated with sepsis (10–100 nM) [25,42].
For receptor blockade studies pfGPI, the C5aR blocking antibody
(Serotec, S5/1, 5 mg/mL) or an isotype control (eBioscience,
eBM2a, 5 mg/mL) was added to culture medium just prior to
stimulation with 50 nM C5a. Culture supernatants were collected
aseptically at times indicated. IL-6, TNF, IL-1b, and IL-10 were
measured by Cytometric Bead Array (CBA) (BD Biosciences,
human inflammation kit). IL-8, monocyte chemoattractant
protein-1 (MCP-1), and macrophage inflammatory protein-1a
and - b (MIP-1a and MIP-1b) and sFlt-1 (sVEGFR-1) were
measured by ELISA (R&D Systems).
Flow cytometry
PBMCs (2.0610
6) were blocked in 20% serum for 20 min at
4uC. Cells were then stained for CD14-APC (eBioscience, 61D3,
100 uL/mL) and CD88-PE or isotype IgG1-PE (BD Biosciences,
D53-1473, 150 uL/mL and eBioscience, P3, 150 uL/mL) for
30 min at 4uC. Cells were fixed in 1% paraformaldehyde/PBS
overnight and analyzed on a Becton Dickinson FACS Calibur flow
cytometer. Data was analyzed using FlowJo software. A minimum
of 50,000 events were collected. Positive background PE staining
in isotype samples was subtracted from respective CD88-PE
stained samples and then reported as specific CD88 staining.
Statistical analysis
Data are expressed as means6SEM, unless otherwise noted.
For continuous variables a Student’s t test or one-way ANOVA
with Bonferonni post-tests was used to compare means. Non-
parametric tests (Mann-Whitney or Kruskall-Wallis) were used to
compare groups where parametric test conditions were not met.
Synergism was determined by the interaction term of a two way
ANOVA (C5a*GPI). Synergism in the time course was deter-
mined using the cumulative cytokine levels after 48 hours by
performing a two way ANOVA and examining the interaction
term. Significance in the C5a receptor blockade experiments was
C5a in Placental Malaria
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levels of cytokines differed between cells treated with pfGPI alone,
or anti-CD88 plus C5a and pfGPI, or student’s t-test by comparing
the isotype and anti-CD88 co-treated (C5a and pfGPI) groups after
correcting for the background levels observed in media controls. In
cases where C5a receptor blockade resulted in values of ‘‘0’’, a one
sample t-test was used to determine whether the isotype C5a and
pfGPI co-treated groups differed from a hypothetical value of ‘‘0’’.
Correlation of peripheral parasitemia to placental parasitemia was
determined using Spearman correlation. Experiments were
performed in duplicate or triplicate and repeated as indicated in
the figure legends. Statistical analysis of experimental replicates is
found in the supporting information files (Supporting Information
S1, S2, S3, S4). Differences with p,0.05 were considered
significant. Statistical analysis was performed using GraphPad
Prism and SPSS.
Study participants
Plasma samples were collected at time of delivery from the
peripheral blood and placental blood of primigravid women, living
in an area of holoendemic malaria transmission in Western
Kenya, with and without placental malaria infection as described
previously [7]. Malaria infection was evaluated by examination of
Giemsa-stained peripheral and placental thick and thin blood
smears by light microscopy. Percent parasitemia was estimated by
counting a minimum of 1000 erythrocytes and calculated using the
following formula: (# infected erythrocytes/total # erythrocytes)
6100. Women who tested positive for HIV were excluded. This
study was approved by the institutional review boards of the
University of Georgia, the Kenya Medical Research Institute and
the Centers for Disease Control and Prevention, Atlanta, Georgia,
United States. Written informed consent was obtained from all
participants.
Results
CSA- and CD36-binding PEs activate C5 and pfGPI
induces C5a receptor expression
The pro-inflammatory anaphylatoxin C5a has been implicated
in mediating deleterious host responses to bacterial and fungal
agents [22,25]. To confirm that CSA-binding PEs were capable of
activating the complement system and thus generating C5a, serum
from malaria-naı ¨ve donors was added to mature stage CS2 PEs or
uRBCS. Compared to uRBCs or controls, C5 activation was only
observed in the presence of PEs (Figure 1A) (mean C5a levels:
CS2 PEs 24.77 ng/mL [95% confidence interval (CI) 2.229–
47.30], E8B PEs 26.19 ng/ml [95% CI 210.44–62.82], uRBCs
7.114 ng/mL [95% CI 5.922–8.306], control 7.242 ng/mL [95%
CI 4.116–10.37]; CS2 PEs vs. uRBCs p,0.001 Student’s t-test).
Non-PM PEs (E8B) also activated C5 (E8B PEs vs. uRBCs
p,0.001 Student’s t-test).
In order to respond to activated C5, cells must express a C5a
receptor. Previous studies report that C5a responsiveness increases
following cellular stimulation [43]. To determine the effect of
pfGPI on monocyte C5aR (CD88) expression, PBMCs were
incubated as above with pfGPI or media control for 24 or
48 hours, and C5aR and CD14 expression (used to define
monocytes) was determined by flow cytometry. Compared to
media only control cells, a significant increase in the number of
monocytes expressing C5aR (Figure 1B) was observed (mean:
media 1.2% [95% CI 20.2–2.7] vs. pfGPI 3.0 [95% CI 1.5–4.4]
p=0.0279 by Student’s t-test). The density of the C5aR, as
determined by the mean fluorescent intensity on monocytes
already expressing the receptor, was unchanged (data not shown).
C5a potentiates pfGPI-induced inflammatory responses
C5a has been shown to enhance TLR-mediated pro-inflamma-
tory responses to microbial products such as LPS, contributing to
sepsis syndromes [22,25,44,45]. The parasite product pfGPI is
recognized by TLR2 and is believed to be a mediator of the
inflammatory response that characterizes severe malarial syn-
dromes [10,44–46]. To assess whether C5a would amplify pfGPI-
induced pro-inflammatory responses, we treated PBMCs with
increasing concentrations of recombinant human C5a (0, 1, 5, 10,
50, and 100 nM) with or without pfGPI for 24 hours and
determined the production of IL-6 and TNF by ELISA. We
observed a dose-dependent potentiation of pfGPI-induced IL-6
and TNF production by C5a (Figure 2A and B; two-way
ANOVA (C5a*GPI), p,0.0001).
C5a Receptor blockade inhibits enhanced cytokine
responses
Elevated levels of TH
1 cytokines have been implicated in PM
pathogenesis and adverse pregnancy outcomes [14,16,47]. In
Figure 1. Parasitized erythrocytes (PEs) induce C5 activation and pfGPI upregulates C5aR expression on monocytes. (A) Serum from
malaria-naı ¨ve donors was added to mature stage CS2 (CSA binding) PEs or E8B (ICAM-1 and CD36 binding), uninfected red blood cells (uRBCs) or
media for 30 min and supernatants were assayed for C5a by ELISA. Increased C5a levels were observed in the supernatants of PEs compared to uRBC
or control, (Student’s t-test: uRBCs vs. Mature PEs ***p,0.001). Data are presented as means6SEM and are representative of four independent
experiments for CS2 parasites and two independent experiments for CD36-binding parasites. (B) Human PBMCs were stimulated with pfGPI or
unconjugated gold beads alone as a control for 24 h. Expression of C5a receptor was determined by flow cytometry on monocytes (CD14). The
percentage of monocytes expressing C5aR was significantly higher for pfGPI-treated versus media control cells, (Student’s t-test: *p=0.0279). Data are
presented as means6SEM and are representative of two independent experiments.
doi:10.1371/journal.pone.0004953.g001
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induced cytokine production, we treated PBMCs with C5a
(50 nM) and pfGPI (HPLC-purified, 300 ng/mL) for 48 hours.
Supernatants were collected at baseline, 1, 2, 4, 6, 8, 12, 24 and
48 hours and assayed for inflammatory cytokines using a
cytometric bead array. To examine the role of C5a-C5aR
interactions in the observed inflammatory responses, we also
performed parallel experiments including monoclonal antibody
blockade of the C5a receptor. pfGPI-stimulated cytokines,
including IL-6, TNF, IL-1b and IL-10, were synergistically
induced in the presence of C5a (Figure 3A–D: two-way ANOVA
on cumulative cytokine levels (C5a*GPI); p,0.0001 for IL-6,
p=0.0124 for TNF, p=0.0418 for IL-1b and p,0.0001 for IL-
10). A significant reduction in cytokine production was observed in
experiments using anti-C5aR blocking antibody compared to its
isotype control for all cytokines measured (Figure 3E–H:
repeated measures ANOVA). Further analysis (repeated measures
ANOVA) was performed to determine whether C5aR blockade
returned cytokine production to levels for cells treated with pfGPI
alone. In the presence of anti-C5aR, production of IL-6, TNF,
and IL-1b was returned to levels that were not significantly
different from pfGPI alone (p.0.05). However, this was not true
for IL-10 (p=0.0101).
C5a potentiates secretion of chemokines and the
angiogenesis inhibitor sFlt-1
The infiltration of monocytes into the placenta during PM is
associated with adverse birth outcomes [15,48,49]. Furthermore,
elevated levels of the anti-angiogenic factor sFlt-1 (sVEGFR-1)
have been causally implicated in placental dysfunction, growth
restriction and fetal loss [32,37]. In order to determine whether
C5a could potentiate the induction of chemokines involved in the
recruitment of monocytes and the anti-angiogenic factor sFlt-1, we
incubated PBMCs with C5a, pfGPI, or media controls with or
without C5aR blocking antibody or an isotype control antibody
and measured IL-8 (CXCL8), MCP-1 (CCL2), MIP-1a (CCL3),
MIP-1b (CCL4), and sFlt-1 (sVEGFR-1) by ELISA (Figure 4). In
the C5a and pfGPI co-treated group, synergistic induction of all
factors was observed by two-way ANOVA (C5a*GPI; p=0.0265
for IL-8, p=0.0010 for MCP-1, and p,0.0001 for MIP-1 a, MIP-
1b and sFlt-1). Blocking C5aR inhibited the augmented secretion
of all chemokines with the exception of IL-8 (Figure 4A–E:
Student’s t-test p=0.0388for MCP-1, p=0.0005 for MIP1-a,
p=0.0002 for MIP1-b). Blockade of the C5aR reduced levels of
sFlt-1, but the differences did not consistently reach statistical
significance (see supporting information file S4).
C5a is increased in PM and is associated with higher
placental parasite burdens
In order to extend our observations to the in vivo setting, we
examined C5a levels in malaria-exposed women (Table 1 and 2).
We analyzed C5a levels in the peripheral and placental plasma of
HIV negative primigravid women with or without PM from
Kisumu, Kenya. Peripheral C5a levels were significantly increased
in women with PM (Figure 5A: mean C5a levels; PM negative:
98.85 ng/mL [95% CI 84.14–113.6] vs. PM positive: 147.1 ng/
mL [95% CI 96.81–197.3] p=0.01 by Student’s t-test two-tailed
test on log transformed data). Furthermore, C5a was significantly
elevated in the placental plasma of women with PM (Figure 5B:
mean C5a levels; PM negative: 69.07 ng/mL [95% CI 58.17–
79.98] vs. PM positive: 104.0 ng/mL [95% CI 73.10–135.0]
p=0.0264 by Student’s t-test two-tailed test on log transformed
data). No significant differences were observed between the ages of
PM positive vs. PM negative women; however, primigravid
women with PM had significantly lower hemoglobin levels,
consistent with the destruction of maternal erythrocytes associated
with malarial infection (Table 1 and 2).
Discussion
This study provides the first evidence implicating excessive
activation of the complement component C5 and the induction of
anti-angiogenic factors in the pathogenesis of PM. We demon-
strate that PEs and parasite products (pfGPI) activated C5 and
induced C5a receptor expression (Figure 1). Further, C5a and
pfGPI induced synergistic production of inflammatory cytokines,
chemokines and an anti-angiogenic factor associated with adverse
pregnancy outcomes (Figures 2, 3&4). A role for C5a-C5aR was
confirmed by inhibiting inflammation with C5aR blockade
(Figures 3&4). These findings were extended to the in vivo
setting, where primigravid women with PM were shown to have
elevated C5a levels in both peripheral and placental plasma
(Figure 5).
The generation of C5a is normally tightly controlled and, under
physiological conditions, C5a enhances the effector function of
macrophages and neutrophils, contributing to effective innate
Figure 2. C5a potentiates pfGPI-induced inflammatory cytokines in a dose-dependent manner. Human PBMCs were stimulated with
varying concentrations of recombinant human C5a (0, 1, 5, 10, 50, 100 nM) for 24 hours, with or without pfGPI. Culture supernatants were collected
and assayed for IL-6 (A) and TNF (B) by ELISA. Data were analyzed by two-way ANOVA and demonstrate an interaction effect (C5a*pfGPI) for IL-6
(***p,0.0001) and for TNF (***p,0.0001). Data are presented as means6SEM of three independent experiments.
doi:10.1371/journal.pone.0004953.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4953Figure 3. C5a potentiates pfGPI-induced inflammatory cytokines and this effect is abrogated by C5a receptor blockade. Human
PBMCs were cultured with unconjugated gold beads (media control), unconjugated gold beads and C5a (50 nM), pfGPI (300 ng/mL), or a
combination of C5a and pfGPI. (A–D) Supernatants were assayed for IL-6 (A), TNF (B), IL-1b (C), and IL-10 (D). A significant interaction effect between
C5a and pfGPI was observed for all cytokines tested. p,0.0001 for IL-6, p=0.0124 for TNF, p=0.0418 for IL-1b and p,0.0001 for IL-10 (by two-way
ANOVA on cumulative cytokine production over 48 h). Data are representative of three independent experiments. (E–H) Human PBMCs were treated
with an a-CD88 mAb (5 mg/mL) to block the C5a receptor or an appropriate isotype control and exposed to either unconjugated gold beads (media
control) or a combination of C5a (50 nM) and pfGPI (300 ng/mL) for 48 h. Supernatants were assayed for IL-6 (E), TNF (F), IL-1b (G) and IL-10 (H).
Cytokine production was significantly reduced upon C5a receptor blockade; p=0.0005 for IL-6, p=0.0028 for TNF, p=0.0479 for IL-1b and p=0.0191
for IL-10 (repeated measures ANOVA comparing cytokine levels between isotype control mAb and a-CD88 mAb groups co-treated with C5a and
pfGPI). Values shown are corrected for background levels observed in the media controls, and are presented as means6SEM. Data are representative
of two independent experiments.
doi:10.1371/journal.pone.0004953.g003
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systemic C5a suggests a loss of regulation of complement
activation. Elevated C5a levels are associated with a number of
deleterious impacts on host innate defence, including defects in
phagocyte and endothelial cell function, potentiated chemokine
and cytokine secretion to bacterial components such as LPS, and
lymphoid apoptosis (reviewed in [22,25]).
There are several mechanisms by which malaria may induce
excessive complement activation, thereby contributing to the
pathophysiologic mechanisms underlying PM. We observed that
mature stage PEs are capable of generating C5a and a bioactive
product of parasite rupture, pfGPI can result in an increase in
monocytes expressing the C5aR. These observations suggest the
potential for an autocrine loop, resulting in augmented inflam-
matory and angiogenic responses that may act in concert to
mediate or amplify placental and fetal injury.
Our observations of malaria-induced C5a are consistent with
studies of severe malaria and experimental malaria challenge
models that report activation of the complement system [50–52].
In experimental human malaria infection, complement activation
was observed prior to microscopic detection of parasitemia [50].
Similarly, a recent study of P. berghei ANKA implicated C5a as an
early mediator of experimental cerebral malaria [53]. In the latter
study, C5a levels were elevated prior to the onset of symptoms
suggesting a role for C5a as an initiating or amplifying factor in
malaria pathogenesis. Our observations are further supported by
the findings of a recent genome-wide analysis of PM, where
selected complement genes as well as C5aR were shown to be
upregulated [54].
During sepsis the excess activation of C5 has been associated
with enhanced secretion of pro-inflammatory mediators in
response to TLR ligands such as LPS [55]. Similarly pfGPI has
Figure 4. C5a potentiates secretion of pfGPI-induced chemokines and the anti-angiogenic factor sFlt-1. Human PBMCs were treated
with either unconjugated gold beads (media control), unconjugated gold beads and C5a (50 nM), pfGPI (300 ng/mL), or a combination of C5a and
pfGPI for 48 h. Where indicated PBMCs were treated with either 5 mg/mL of a-CD88 mAb to block the C5a receptor or an appropriate isotype control
and were exposed to C5a and pfGPI. Supernatants were assayed for IL-8 (A), MCP-1 (B), MIP-1a (C), MIP-1b (D) and sFlt-1 (E). A significant interaction
effect between C5a and pfGPI was observed; *p=0.0265 for IL-8, **p=0.0010 for MCP-1, * p=0.0177 for sFlt-1, and ***p,0.0001 for MIP-1 a, and MIP-
1b (by two-way ANOVA). C5a receptor blockade significantly reduced the levels of MCP-1 (* p=0.0388), MIP-1a (*** p=0.0005), and MIP-1b (***
p=0.0002) (by student’s t-test). Data are presented as means6SEM and are representative of three independent experiments.
doi:10.1371/journal.pone.0004953.g004
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dependant manner [10,56]. Additional studies will be needed to
determine if the synergistic induction of inflammatory and
angiogenic factors observed with pfGPI-C5a are also TLR-
dependent.
In our in vitro model, C5aR blockade abrogated the potentiated
inflammatory responses that are believed to be central to the
pathogenesis of PM. However, a different response was observed
for IL-10. While IL-10 production was reduced by C5aR
blockade, the levels did not return to those observed with pfGPI
alone. We speculate that this may be attributable to the expression
of the alternate C5a receptor, C5L2, which has been shown to
promote TH
2 skewing [57] as well as have inflammatory effects in
experimental sepsis [58]. Future studies will be required to
investigate the role of pfGPI and other parasite products on the
expression of C5L2. When cells were treated with pfGPI and C5a,
IL-10 was induced earlier than with pfGPI alone (Figure 3D).
This may have important implications in vivo since TGF-b and IL-
10 regulate inflammatory responses. Early IL-10 may impair TH
1-
mediated parasite clearance during malaria infection and
increased IL-10 levels have been reported in PM [59].
Monocyte infiltration into the placental intervillous space has
been associated with poor birth outcomes including the risk of low
birth weight infants [15,48,49,60,61]. Chemokines function as
specific chemoattractants for leukocytes. IL-8 plays a role in
neutrophil and monocyte migration, while the b-chemokines are
involved in macrophage migration. High levels of macrophage-
derived IL-8 during PM have been associated with IUGR [47].
Elevated levels of MIP-1a, MIP-1b and MCP-1 have been
observed in PM and it is likely that these chemokines are derived
from both maternal (leukocyte) [6,8] and fetal (syncytiotropho-
blast) sources [11,62]. As with cytokines, C5a and pfGPI
synergistically induced chemokines, and this effect was abrogated
for the b-chemokines by blocking the C5aR (Figure 4A–D). No
significant difference for IL-8 production was found between cells
treated with anti-C5aR versus an isotype control due to the
variation in the latter group. However, there was no difference
between cells treated with pfGPI alone or with anti-C5aR plus C5a
and pfGPI, indicating that blocking the C5aR inhibits the effect
attributable to C5a.
Peak prevalence of malaria infection during pregnancy occurs
between 13–20 weeks gestation and gradually falls as gestation
increases [63]. This coincides with the second wave of trophoblast
invasion of the maternal spiral arteries (16–18 weeks). It is
hypothesized that PM may impair transformation of the maternal
vasculature leading to placental dysfunction [64,65]. One protein
Figure 5. Primigravid women with placental malaria (PM) have
increased levels of C5a in peripheral and placental plasma. C5a
levels were assayed in peripheral and placental plasma by ELISA.
Samples were obtained from HIV negative primigravid women at time
of delivery in Kisumu, western Kenya. C5a levels were significantly
higher in (A) peripheral plasma of placenta malaria positive (PM+,
n=21) vs. placenta malaria negative (PM2, n=45) women, *p=0.01 by
two-tailed Student’s t-test on log transformed data; and (B) in placenta
plasma of placenta malaria positive (PM+, n=24) vs. placenta malaria
negative (PM2, n=47) women, *p=0.0264 by Student’s t-test two-
tailed test on log transformed data.
doi:10.1371/journal.pone.0004953.g005
Table 1. Characteristics of women tested for C5a in peripheral blood.
Group (n) Age Hemoglobin % Parasitemia Hemozoin (% Score)
mean6SD mean6SD Peripheral Placental mean6SD
mean6SD mean6SD
Control (47) 19.0462.64 11.8962.92 NA NA 060.00
Malaria (24) 18.4862.48 9.9562.37 { 1.5461.90 5.70610.25 7.0768.47
Abbreviations: Hemoglobin (g/dL), % parasitemia (% infected: non-infected erythrocytes), Hemozoin % Score (# pigment containing WBC/ 300WBC).
{p,0.001 (Student’s t-test).
doi:10.1371/journal.pone.0004953.t001
Table 2. Characteristics of women tested for C5a in placental blood.
Group (n) Age Hemoglobin % Parasitemia Hemozoin (% Score)
mean6SD mean6SD Peripheral Placental mean6SD
mean6SD mean6SD
Control (45) 18.5862.74 12.3662.75 NA NA 0.0560.34
Malaria (21) 18.1362.03 10.3663.09){ 1.4161.79 4.4466.46 7.95611.98
Abbreviations: Hemoglobin (g/dL), % parasitemia (% infected: non-infected erythrocytes), Hemozoin % Score (# pigment containing WBC/ 300WBC).
{p,0.001 (Student’s t-test).
doi:10.1371/journal.pone.0004953.t002
C5a in Placental Malaria
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4953that may play a role in impaired angiogenesis is the anti-
angiogenic factor sFlt-1. This alternatively spliced soluble variant
of VEGFR-1 binds and sequesters placental growth factor and
vascular endothelial growth factor. Excess sFlt-1 has been shown
to inhibit placental cytotrophoblast differentiation and invasion
[33]. Increased sFlt-1 levels have been implicated in the
pathogenesis of placentation associated with pre-eclampsia and
IUGR [34–36] and have been shown to predict the development
of pre-eclampsia [35]. sFlt-1 can be produced extra-placentally by
monocytes treated with C5a [32]. Therefore, we determined
whether C5a and pfGPI would potentiate sFlt-1 production from
mononuclear cells. We show that sFlt-1 was synergistically induced
by co-stimulation with these molecules and that this effect was
reduced but not consistently inhibited by C5aR blockade
(Figure 4E). We postulate this may be due to different PBMC
donors, as FLT1 genotype has been associated with differing sFlt-1
levels in the peripheral blood of primigravid women, as well as
PBMC responsiveness to LPS in vitro [66]. Furthermore, the study
by Muehlenbachs et al., provides the first evidence that both fetal
and maternal genotype may contribute to immune responses to
PM [66]. Taken together, these data suggest a putative mechanism
for impaired angiogenesis and placental dysfunction during PM.
In order to extend these observations to human infection, we
measured C5a levels in the peripheral blood of a cohort of
malaria-exposed primigravid Kenyan women and we measured
C5a levels in the placental blood of a similar cohort of malaria-
exposed primigravid women at time of delivery (Table 1–2)
Significantly increased levels of C5a were found in peripheral
blood (Figure 5A) and the placental blood (Figure 5B) of
pregnant women with PM compared to those without. These
results provide the first evidence that C5a levels are elevated in
women with PM. However, these findings will need to be
confirmed in larger prospective clinical studies. It will be of
interest to also examine how C5a levels change with respect to
other disease parameters, including parasitemia and mononuclear
cell infiltrates in larger populations.
Figure 6. Proposed mechanism for C5a-mediated dysregulation of the placental environment in PM. Mature schizonts activate C5 and
rupture releasing parasite components containing GPI that induce expression of C5aR and activate macrophages. The concomitant expression of
C5aR and generation of C5a represent a potential autocrine mechanism by which C5a can amplify inflammation in P. falciparum malaria resulting in
the excessive cytokine and chemokine responses that characterize PM. The dysregulated production of cytokines, chemokines and the anti-
angiogenic factor sFlt-1 contribute to placental dysfunction, intrauterine growth restriction and low birth weight infants.
doi:10.1371/journal.pone.0004953.g006
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enhanced cytokine and chemokine responses that characterize PM
and in the induction of sFlt-1, an anti-angiogenic factor associated
with abnormal placental development and poor birth outcomes
(Figure 6). Our findings that disruption of the C5a-C5aR
interaction inhibits inflammatory and anti-angiogenic responses
to malaria suggest anti-C5a-C5aR strategies as potential thera-
peutic approaches for PM [67].
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